Geographic and Racial Disparities in Access to Chimeric Antigen Receptor–T Cells and Bispecific Antibodies Trials for Multiple Myeloma

Chimeric Antigen Receptor T-Cell Therapy in Multiple Myeloma—Challenges and Potential Solutions

(2022) Samer Al Hadidi et al.   JAMA Oncology

Enrollment of Black Participants in Pivotal Clinical Trials Supporting US Food and Drug Administration Approval of Chimeric Antigen Receptor–T Cell Therapy for Hematological Malignant Neoplasms

(2022) Samer Al Hadidi et al.   JAMA Network Open

Teclistamab in Relapsed or Refractory Multiple Myeloma

(2022) Philippe Moreau et al.   NEW ENGLAND JOURNAL OF MEDICINE

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

(2021) Nikhil C. Munshi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study

(2021) Saad Z Usmani et al.   LANCET

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

(2021) Jesus G Berdeja et al.   LANCET

Health disparities experienced by Black and Hispanic Americans with multiple myeloma in the United States: a population-based study

(2021) Samer Al Hadidi et al.   LEUKEMIA & LYMPHOMA

Participation of African American Persons in Clinical Trials Supporting U.S. Food and Drug Administration Approval of Cancer Drugs

(2020) Samer Al Hadidi et al.   ANNALS OF INTERNAL MEDICINE

Treatment Options for Triple-class Refractory Multiple Myeloma

(2019) Joseph Mikhael   Clinical Lymphoma Myeloma & Leukemia